| 000 | 01840 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250512005142.0 | ||
| 264 | 0 | _c19890927 | |
| 008 | 198909s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1989.7.9.1351 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSaez, R | |
| 245 | 0 | 0 |
_aPhase I clinical investigation of amonafide. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cSep 1989 |
||
| 300 |
_a1351-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdenine |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImides |
| 650 | 0 | 4 |
_aIsoquinolines _xadverse effects |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNaphthalimides |
| 650 | 0 | 4 | _aOrganophosphonates |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 700 | 1 | _aCraig, J B | |
| 700 | 1 | _aKuhn, J G | |
| 700 | 1 | _aWeiss, G R | |
| 700 | 1 | _aKoeller, J | |
| 700 | 1 | _aPhillips, J | |
| 700 | 1 | _aHavlin, K | |
| 700 | 1 | _aHarman, G | |
| 700 | 1 | _aHardy, J | |
| 700 | 1 | _aMelink, T J | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 7 _gno. 9 _gp. 1351-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1989.7.9.1351 _zAvailable from publisher's website |
| 999 |
_c2555160 _d2555160 |
||